What are the components of Atripla?

Atripla is a fixed-dose combination antiretroviral medication used for the treatment of HIV. The components of Atripla are specifically Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by inhibiting the reverse transcriptase enzyme critical for HIV replication. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), which also plays a crucial role in disrupting the HIV life cycle, while Tenofovir Disoproxil Fumarate, also an NRTI, contributes to the overall effectiveness of the regimen by preventing viral replication.

This combination provides a potent therapy by utilizing different mechanisms of action to suppress the viral load effectively and is often selected for its convenience of being a single tablet regimen. Understanding these components is important for recognizing how they function together to manage HIV and the rationale behind their use in combination therapy.